Use of cGMP-phosphodiesterase inhibitors in methods and compositions to treat impotence

摘要

PCT No. PCT/EP96/03024 Sec. 371 Date Mar. 10, 1998 Sec. 102(e) Date Mar. 10, 1998 PCT Filed Jul. 11, 1996 PCT Pub. No. WO97/03675 PCT Pub. Date Feb. 6, 1997The use of (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione, (3S 6R,12aR)-2,3,6,7,12,12a-hexahydro-2,3-dimethyl-6-(3,4-methylenedioxyhenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione, and physiologically acceptable salts and solvates thereof, in methods and compositions for the treatment of impotence.